|
**Overview**: Catecholamines Panel**Introduction**: The Catecholamines Panel is a diagnostic tool designed to assess adrenal function using urine or plasma samples. In India, pheochromocytoma/paraganglioma (rare but serious) and neuroblastoma (common in children) cause catecholamine excess (epinephrine, norepinephrine, dopamine), leading to hypertension, palpitations, sweating. High morbidity from underdiagnosis in rural areas, limited endocrinology access, delayed surgical resection leading to cardiovascular complications. Per endocrinology practices aligned with ICMR guidelines, the test employs HPLC for fractionated catecholamine analysis over 1-2 days with high sensitivity/specificity, valuable for confirming excess and guiding imaging/surgery. This diagnostic falls under adrenal function screening and targets patients with paroxysmal hypertension or adrenal mass suspicion, addressing accurate detection to prevent crises. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its urine/plasma-based approach ensures reliable detection.**Other Names**: Catecholamines Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/endocrinology, compliant with 2025 standards.**Historical Milestone**: HPLC standard; in India, used in hypertension clinics.**Purpose**: The test assesses 3 parameters including epinephrine to guide adrenal function evaluation, detect catecholamine excess, inform tumor localization.**Test Parameters**: 1. Epinephrine, 2. Norepinephrine, 3. Dopamine.**Pretest Condition**: No fasting required; patients should report hypertension, palpitations, sweating, or adrenal mass history.**Specimen**: 10 mL urine in 1 sterile container or plasma in EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on hypertension episodes, sweating, headache, family endocrine history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated catecholamine excess including stroke, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using HPLC by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or medications can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated catecholamines indicate pheochromocytoma, necessitating specialist input. Normal may require follow-up if symptoms persist.**Specialist Consultation**: Endocrinologists should be consulted for management.**Additional Supporting Tests**: Metanephrines, imaging for confirmation.**Test Limitations**: Diet/medications interfere; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Pheochromocytoma Studies India 2023. |
